Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

W William Cox (NPI 1114912094)

Field	Value
Entity Type	Individual
Organization	W William Cox
Address	1640 Cowles St
City	Suite 1
State	AK
ZIP	99701
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 15, 2005

Payer Source	Total Paid
Medicare	$472.4K
Medicaid	$0

Key Findings

This provider’s billing mix is consistent with a hematology/oncology infusion practice: the dominant procedure is pembrolizumab administration (J9271) complemented by chemotherapy administration codes such as 96413 and multiple infusion add-on codes (96417, 96415, 96367). Office evaluation and management codes (99213, 99214, 99215) also appear across the top codes, indicating the practice combines infusion services with clinic follow-up and management visits rather than being purely an inpatient or surgical specialty.

Revenue is highly concentrated in a single drug line: the top three Medicare codes (J9271, 99213, and 96413) account for 81.6% of the provider’s total Medicare revenue, and J9271 alone represents 70.4% of Medicare revenue with $327.6K attributed to that code. This concentration means most Medicare dollars reported ($472.4K total Medicare revenue) are tied to pembrolizumab administration rather than a broad mix of services.

The provider appears effectively single‑payer in this dataset: Medicare revenue totals $472.4K while there is no Medicaid billing on file. The absence of Medicaid activity indicates the provider’s public-payer exposure is centered on Medicare and any Medicaid-related population or contract exposure is minimal or non‑existent in the available claims.

Despite the outsized revenue share from J9271, the provider is a modest participant in national pembrolizumab billing volume: J9271 shows 7.8K claims and $42 avg paid/claim but the code ranks #1430 of 1841 providers nationally (21th percentile; typical, unremarkable volume for this code). By contrast, office visit code 99213 is comparatively strong in scale (373 claims, $85 avg paid/claim) and ranks #43482 of 457151 providers nationally (90th percentile; typical, unremarkable volume for this code), suggesting the practice maintains above‑median clinic visit volume even if it is not a top national administrator of the drug itself.

Operational signals in the code mix point to an outpatient infusion model with continuity services: presence of G0498 (initiation and continuation of infusion with portable pump), multiple infusion add-on codes (96417, 96415), and follow‑on IV infusion codes (96367, 96375) indicates the practice not only initiates infusions but also manages multi‑drug or extended infusion sessions. The combination of these infusion administration codes with diagnostic/biopsy code 38222 (21 claims, $75 avg paid/claim, $1.6K revenue) suggests they offer both therapeutic infusions and in‑office diagnostic procedures.

The claim-level economics reflect the billing unit structure for high-cost oncology drugs: J9271 shows a low average paid per claim ($42 avg paid/claim) but very high aggregate revenue ($327.6K) and claim count (7.8K claims), consistent with a per‑milligram J‑code that accumulates revenue through many billed units rather than a high per‑claim payment. Other oncology drug codes with large claim counts but low per‑claim averages (for example J0640 with 544 claims at $3 avg paid/claim) reinforce that unit-based drug billing is the major revenue engine.

Longitudinal presence is established: the NPI was enumerated on 2005-09-15 (~21 years ago), indicating an enduring practice footprint that could support established referral patterns and payer relationships. That tenure, combined with the concentrated oncology infusion activity, suggests a stable clinical role even if the provider is not a dominant national player for the leading drug code.

The heavy reliance on a single chemotherapy/immunotherapy code creates concentration sensitivity: because J9271 accounts for 70.4% of Medicare revenue, changes in utilization patterns, unit pricing, or payer coverage for that specific drug or its billing units would materially affect practice revenue. Combined with no recorded Medicaid revenue, reimbursement changes in the Medicare program would have outsized financial impact on the provider compared with practices having a more diversified payer mix.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	7,800	$40	$327.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	370	$90	$31.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	190	$110	$20.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	170	$120	$20.3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	100	$140	$12.8K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	30	$220	$6.1K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	30	$150	$4.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	20	$180	$4K
99212	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,…	80	$50	$3.7K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	130	$30	$3.6K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

W William Cox — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	11	10	13,300	$40	$609.5K
96413	14	20	230	$110	$30.2K
99214	368	1,210	90	$100	$16.2K
J9217	13	20	100	$130	$14.8K
99215	302	400	40	$150	$11K
99213	70	1,290	70	$70	$8.5K
G0498	8	10	50	$150	$7.5K
99205	64	140	30	$190	$7.4K
99204	313	460	30	$140	$6.1K
96417	11	20	100	$60	$5.3K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with W William Cox, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Aimee Johnson	AK	Physician Assistant	$914.7K	$0
Angela Emerson	AK	Physician Assistant	$403.8K	$0
Jacqueline Cox	AK	Hematology & Oncology Physician	$403.3K	$0
Britni Browning	AK	Physician Assistant	$256.7K	$0
Dennis Beckworth	GU	Medical Oncology Physician	$6K	$0

Nearby Providers

Other providers in the same ZIP code as W William Cox, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tanana Chiefs Conference	AK	Multi-Specialty Clinic/Center	$0	$107.5M
Fairbanks Memorial Hospital, LLC	AK	General Acute Care Hospital	$0	$83.6M
Fairbanks Resource Agency Inc	AK	Community/Behavioral Health Agency	$0	$48M
Presbyterian Hospitality House	AK	Emotionally Disturbed Childrens' Residential Treatment Facility	$0	$34.9M
Fairbanks Native Association	AK	Substance Abuse Rehabilitation Facility	$0	$32.6M
Tanana Chiefs Confenerce	AK	Transportation Broker	$0	$24.1M
Tanana Chiefs Conference	AK	Community/Behavioral Health Agency	$0	$17M
Tanana Chiefs Conference	AK	Multi-Specialty Clinic/Center	$0	$16.3M
Restore LLC	AK	Substance Use Disorder Rehabilitation Clinic/Center	$0	$16.3M
Tanana Valley Clinic LLC	AK	Multi-Specialty Clinic/Center	$0	$15.2M

W William Cox — Billing Profile & Reimbursement Data

Sign up for W William Cox — Billing Profile & Reimbursement Data policy alerts

W William Cox — Billing Profile & Reimbursement Data

Sign up for W William Cox — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References